A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055
Diane E. Gingrich, Robert L. Hudkins(State Street (United States)), D. Rajagopala Reddy(Protein Express (United States)), John P. Mallamo, Mohamed Iqbal(Protein Express (United States)), Shi Yang(Protein Express (United States)), Mark A. Ator, Mark S. Albom, Craig A. Dionne, Lisa D. Aimone, Sheryl L. Meyer(NRG Oncology), Candy Robinson, Jeffry L. Vaught(Kyowa Kirin (Japan)), Thelma S. Angeles, Bruce Ruggeri
Cited by 74
Related Papers
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
|Proceedings of the National Academy of Sciences|2008|723
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
|ACS Chemical Neuroscience|2011|436
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives
|Journal of Medicinal Chemistry|1997|120
Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors
|Expert Opinion on Drug Discovery|2016|113